Drug resistance is a major problem in Mycobacterium tuberculosis control, and it is critical to identify novel drug targets and new antimycobacterial compounds. We have previously identified an imidazo[1,2-a]pyridine-4-carbonitrile-based agent, MP-III-71, with strong activity against M. tuberculosis. In this study, we evaluated mechanisms of resistance to MP-III-71. We derived three independent M. tuberculosis mutants resistant to MP-III-71 and conducted whole-genome sequencing of these mutants. Loss-of-function mutations in Rv2887 were common to all three MP-III-71-resistant mutants, and we confirmed the role of Rv2887 as a gene required for MP-III-71 susceptibility using complementation. The Rv2887 protein was previously unannotated, but domain and homology analyses suggested it to be a transcriptional regulator in the MarR (multiple antibiotic resistance repressor) family, a group of proteins first identified in Escherichia coli to negatively regulate efflux pumps and other mechanisms of multidrug resistance. We found that two efflux pump inhibitors, verapamil and chlorpromazine, potentiate the action of MP-III-71 and that mutation of Rv2887 abrogates their activity. We also used transcriptome sequencing (RNA-seq) to identify genes which are differentially expressed in the presence and absence of a functional Rv2887 protein. We found that genes involved in benzoquinone and menaquinone biosynthesis were repressed by functional Rv2887. Thus, inactivating mutations of Rv2887, encoding a putative MarR-like transcriptional regulator, confer resistance to MP-III-71, an effective antimycobacterial compound that shows no cross-resistance to existing antituberculosis drugs. The mechanism of resistance of M. tuberculosis Rv2887 mutants may involve efflux pump upregulation and also drug methylation.T uberculosis (TB) is a devastating disease that infects one-third of the world's population and killed 1.5 million people in 2013 (1). TB is caused by Mycobacterium tuberculosis and is challenging and time-consuming to treat. Standard TB treatment is currently 6 months long and involves a 2-month intensive phase consisting of treatment with four antibiotics (isoniazid, rifampin, ethambutol, and pyrazinamide) followed by a 4-month continuation phase (treatment with isoniazid and rifampin only). However, despite this combination therapy, drug resistance is on the rise, and in 2013, there were an estimated 480,000 cases of multidrug-resistant (MDR) TB, which is defined as TB caused by bacteria that are resistant to at least isoniazid and rifampin. These cases require up to 2 years of treatment, but drug resistance is developing even under these conditions, and in 2014, 9% of MDR TB cases were extensively drug resistant (XDR), meaning that they were also resistant to isoniazid, rifampin, a fluoroquinolone, and an injectable anti-TB drug (typically an aminoglycoside) (1). Thus, there is a great need both for new antibiotics to treat M. tuberculosis and for new drug targets that avoid cross-resistance to currently used therapies.O...